Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gabriele Missale

Showing results (71-80 of 111) with videos related to

Pageof 12
Sort By:
Nature Medicine|February 7, 2017
Targeting mitochondrial dysfunction can restore antiviral activity of exhausted HBV-specific CD8 T cells in chronic hepatitis BPaola Fisicaro, Valeria Barili, Barbara Montanini, et al.
Plos One|March 11, 2011
Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphismsMartin Lagging, Galia Askarieh, Francesco Negro, et al.
The Journal of Infectious Diseases|September 9, 2006
Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infectionAna I Romero, Martin Lagging, Johan Westin, et al.
Plos One|February 26, 2013
Impact of soluble CD26 on treatment outcome and hepatitis C virus-specific T cells in chronic hepatitis C virus genotype 1 infectionJonas Söderholm, Jesper Waldenström, Galia Askarieh, et al.
Journal of Hepatology|November 14, 2020
Functional reconstitution of HBV-specific CD8 T cells by in vitro polyphenol treatment in chronic hepatitis BGreta Acerbi, Ilaria Montali, Gennaro Domenico Ferrigno, et al.
Hepatology (Baltimore, Md.)|November 30, 2006
IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infectionMartin Lagging, Ana I Romero, Johan Westin, et al.
Cancer|April 12, 2014
Determinants of alpha-fetoprotein levels in patients with hepatocellular carcinoma: implications for its clinical useEdoardo G Giannini, Giorgio Sammito, Fabio Farinati, et al.
Gastroenterology|October 9, 2007
HCV-specific T-cell response in relation to viral kinetics and treatment outcome (DITTO-HCV project)Massimo Pilli, Alessandro Zerbini, Amalia Penna, et al.
JHEP Reports : Innovation in Hepatology|February 18, 2026
Transcriptional and functional HBV-specific CD8 T cell changes from disease to functional cure in HBeAg-negative chronic hepatitis BMarzia Rossi, Andrea Vecchi, Camilla Tiezzi, et al.
Journal for Immunotherapy of Cancer|November 28, 2023
Randomized, open-label, phase II, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with locally advanced, inflammatory, or early HER2-positive breast cancer-Immun-HER trial (GOIRC-01-2016)Benedetta Pellegrino, Chiara Tommasi, Olga Serra, et al.
Pageof 12

Showing results (71-80 of 111) with videos related to

Sort By:
Pageof 12
Nature Medicine|February 7, 2017
Targeting mitochondrial dysfunction can restore antiviral activity of exhausted HBV-specific CD8 T cells in chronic hepatitis BPaola Fisicaro, Valeria Barili, Barbara Montanini, et al.
Plos One|March 11, 2011
Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphismsMartin Lagging, Galia Askarieh, Francesco Negro, et al.
The Journal of Infectious Diseases|September 9, 2006
Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infectionAna I Romero, Martin Lagging, Johan Westin, et al.
Plos One|February 26, 2013
Impact of soluble CD26 on treatment outcome and hepatitis C virus-specific T cells in chronic hepatitis C virus genotype 1 infectionJonas Söderholm, Jesper Waldenström, Galia Askarieh, et al.
Journal of Hepatology|November 14, 2020
Functional reconstitution of HBV-specific CD8 T cells by in vitro polyphenol treatment in chronic hepatitis BGreta Acerbi, Ilaria Montali, Gennaro Domenico Ferrigno, et al.
Hepatology (Baltimore, Md.)|November 30, 2006
IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infectionMartin Lagging, Ana I Romero, Johan Westin, et al.
Cancer|April 12, 2014
Determinants of alpha-fetoprotein levels in patients with hepatocellular carcinoma: implications for its clinical useEdoardo G Giannini, Giorgio Sammito, Fabio Farinati, et al.
Gastroenterology|October 9, 2007
HCV-specific T-cell response in relation to viral kinetics and treatment outcome (DITTO-HCV project)Massimo Pilli, Alessandro Zerbini, Amalia Penna, et al.
JHEP Reports : Innovation in Hepatology|February 18, 2026
Transcriptional and functional HBV-specific CD8 T cell changes from disease to functional cure in HBeAg-negative chronic hepatitis BMarzia Rossi, Andrea Vecchi, Camilla Tiezzi, et al.
Journal for Immunotherapy of Cancer|November 28, 2023
Randomized, open-label, phase II, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with locally advanced, inflammatory, or early HER2-positive breast cancer-Immun-HER trial (GOIRC-01-2016)Benedetta Pellegrino, Chiara Tommasi, Olga Serra, et al.
Pageof 12